BioRestorative Therapies (BRTX) Stock Price, News & Analysis

Company Overview

BioRestorative Therapies, Inc. engages in the development of therapeutic products and medical therapies using cell and tissue protocols. Its programs provide quality of care for chronic back pain caused by disc degeneration and metabolic disorders, including obesity and diabetes. The company's initial investigational therapeutic product being called BRTX-100 focuses on treating damage by an autologous stem cell product that uses own stem cells that are harvested, cultured, and then injected directly into the affected disc to start the repair process. BioRestorative Therapies was founded on June 13, 1997 and is headquartered in Melville, NY.

Key Stats

• Today's Range: $1.75 to $1.89
• 50-Day Range: $1.41 to $1.83
• 52-Week Range: $1.21 to $2.55
• Volume: 177,584 shs
• Average Volume: 208,237 shs
• Market Capitalization: $14.68 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BRTX Stock Analysis - Frequently Asked Questions

How have BRTX shares performed this year?

BioRestorative Therapies' stock was trading at $1.43 at the start of the year. Since then, BRTX shares have increased by 28.7% and is now trading at $1.84.

When did BioRestorative Therapies' stock split?

BioRestorative Therapies's stock reverse split on the morning of Wednesday, October 27th 2021.The 1-4000 reverse split was announced on Wednesday, October 27th 2021. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, October 27th 2021. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split.

How do I buy shares of BioRestorative Therapies?

Shares of BRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of BioRestorative Therapies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that BioRestorative Therapies investors own include Tonix Pharmaceuticals (TNXP), Vaxart (VXRT), Inovio Pharmaceuticals (INO), Actinium Pharmaceuticals (ATNM), NVIDIA (NVDA), Onconova Therapeutics (ONTX) and American Graphite Technologies (AGIN).

Company Calendar

• Today: 8/29/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Healthcare
• Current Symbol: OTCMKTS:BRTX
• CIK: 1505497
• Web: www.biorestorative.com
• Phone: (631) 760-8100
• Fax: N/A
• Employees: 7
• Year Founded: 1997

Profitability

• EPS (Trailing Twelve Months): ($1.27)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$18.50 million
• Net Margins: -13,728.83%
• Pretax Margin: -13,728.83%
• Return on Equity: -120.47%
• Return on Assets: -114.48%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 14.81
• Quick Ratio: 14.81

Sales & Book Value

• Annual Sales: $605.20 thousand
• Price / Sales: 24.26
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.65 per share
• Price / Book: 0.69

Miscellaneous

• Outstanding Shares: 7,978,000
• Free Float: 3,660,000
• Market Cap: $14.68 million
• Optionable: Not Optionable
• Beta: 76.70